Sindhu R Johnson

List of Publications by Year
in descending order

143 papers	11,457 citations	61984 43 h-index	30922 102 g-index
145 all docs	145 docs citations	145 times ranked	10534 citing authors

#	Article	IF	Citations
1	Response to: Correspondence on "European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) SLE classification criteria item performance" by Bossuyt *et al*. Annals of the Rheumatic Diseases, 2023, 82, e194-e194.	0.9	6
2	Evaluating the Construct of Damage in Systemic Lupus Erythematosus. Arthritis Care and Research, 2023, 75, 998-1006.	3.4	7
3	Response to: ''2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus' by Aringer *et al*' by Cui *et al*. Annals of the Rheumatic Diseases, 2022, 81, e166-e166.	0.9	47
4	Response to: 'Do 2019 European League against rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus also indicate the disease activity?' by Teng *et al*. Annals of the Rheumatic Diseases, 2022, 81, e23-e23.	0.9	3
5	Barriers and Facilitators to Physical Activity for People With Scleroderma: A Scleroderma Patient–Centered Intervention Network Cohort Study. Arthritis Care and Research, 2022, 74, 1300-1310.	3.4	4
6	Assessing the EULAR/ACR classification criteria for patients with systemic lupus erythematosus. Expert Review of Clinical Immunology, 2022, 18, 135-144.	3.0	8
7	COVID-19 Hospitalizations, Intensive Care Unit Stays, Ventilation, and Death Among Patients With Immune-mediated Inflammatory Diseases Compared to Controls. Journal of Rheumatology, 2022, 49, 523-530.	2.0	18
8	Randomized feasibility trial of the Scleroderma Patient-centered Intervention Network Self-Management (SPIN-SELF) Program. Pilot and Feasibility Studies, 2022, 8, 45.	1.2	3
9	American College of Rheumatology Guidance for COVID-19 Vaccination in Patients With Rheumatic and Musculoskeletal Diseases: Version 4. Arthritis and Rheumatology, 2022, 74, e21-e36.	5.6	49
10	Biological and clinical insights from a randomized phase 2 study of an anti-oncostatin M monoclonal antibody in systemic sclerosis. Rheumatology, 2022, 62, 234-242.	1.9	13
11	Management of Calcinosis Cutis in Rheumatic Diseases. Journal of Rheumatology, 2022, 49, 980-989.	2.0	13
12	Advances in SLE classification criteria. Journal of Autoimmunity, 2022, 132, 102845.	6.5	11
13	How the American College of Rheumatology Develops Guidelines. Rheumatic Disease Clinics of North America, 2022, 48, 579-588.	1.9	1
14	Response to: 'New 2019 SLE EULAR/ACR classification criteria are valid for identifying patients with SLE among patients admitted for pericardial effusion' by Sacre *et al*. Annals of the Rheumatic Diseases, 2021, 80, e191-e191.	0.9	3
15	Response to: 'European League against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus: the laboratory immunologist's point of view' by Infantino *et al*. Annals of the Rheumatic Diseases, 2021, 80, e189-e189.	0.9	28
16	Propensity Score Methods in Rare Disease: A Demonstration Using Observational Data in Systemic Lupus Erythematosus. Journal of Rheumatology, 2021, 48, 321-325.	2.0	6
17	Unmet Workplace Support Needs and Lost Productivity of Workers With Systemic Sclerosis: A Path Analysis Study. Arthritis Care and Research, 2021, 73, 423-431.	3.4	15
18	Antirheumatic Disease Therapies for the Treatment of COVID-19: A Systematic Review and Meta-Analysis. Arthritis and Rheumatology, 2021, 73, 36-47.	5.6	52

#	Article	IF	Citations
19	Acquired low immunoglobulin levels and risk of clinically relevant infection in adult patients with systemic lupus erythematosus: a cohort study. Rheumatology, 2021, 60, 1456-1464.	1.9	7
20	American College of Rheumatology Guidance for the Management of Rheumatic Disease in Adult Patients During the COVID‑19 Pandemic: Version 3. Arthritis and Rheumatology, 2021, 73, e1-e12.	5.6	201
21	Reply. Arthritis and Rheumatology, 2021, 73, 548-549.	5.6	0
22	Factors Predictive of Radiographic Progression in Ankylosing Spondylitis. Arthritis Care and Research, 2021, 73, 275-281.	3.4	10
23	New EULAR/ACR 2019 SLE Classification Criteria: defining ominosity in SLE. Annals of the Rheumatic Diseases, 2021, 80, 767-774.	0.9	20
24	European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) SLE classification criteria item performance. Annals of the Rheumatic Diseases, 2021, 80, 775-781.	0.9	37
25	Immunoglobulin levels in systemic lupus erythematosus: A narrative review. Lupus, 2021, 30, 867-875.	1.6	8
26	Natural variability in the disease course of SSc-ILD: implications for treatment. European Respiratory Review, 2021, 30, 200340.	7.1	18
27	Evolving concepts in systemic lupus erythematosus damage assessment. Nature Reviews Rheumatology, 2021, 17, 307-308.	8.0	10
28	Systematic Analysis of the Literature in Search of Defining Systemic Sclerosis Subsets. Journal of Rheumatology, 2021, 48, jrheum.201594.	2.0	6
29	American College of Rheumatology Guidance for COVID‑19 Vaccination in Patients With Rheumatic and Musculoskeletal Diseases: Version 1. Arthritis and Rheumatology, 2021, 73, 1093-1107.	5.6	146
30	American College of Rheumatology Guidance for COVID‑19 Vaccination in Patients With Rheumatic and Musculoskeletal Diseases: Version 2. Arthritis and Rheumatology, 2021, 73, e30-e45.	5.6	61
31	Systemic Lupus Erythematosus Classification and Diagnosis. Rheumatic Disease Clinics of North America, 2021, 47, 501-511.	1.9	15
32	2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Care and Research, 2021, 73, 924-939.	3.4	466
33	2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis and Rheumatology, 2021, 73, 1108-1123.	5.6	339
34	Reply. Arthritis and Rheumatology, 2021, 73, 1769-1770.	5.6	2
35	Epidemiology and Treatment of Peripheral Neuropathy in Systemic Sclerosis. Journal of Rheumatology, 2021, 48, 1839-1849.	2.0	14
36	Response to: Correspondence on "New EULAR/ACR 2019 SLE classification criteria: defining ominosity in SLE" by Whittall Garcia et al. Annals of the Rheumatic Diseases, 2021, , annrheumdis-2021-221014.	0.9	0

#	Article	IF	Citations
37	American College of Rheumatology Guidance for COVID‑19 Vaccination in Patients With Rheumatic and Musculoskeletal Diseases: Version 3. Arthritis and Rheumatology, 2021, 73, e60-e75.	5.6	126
38	Employment outcomes in systemic sclerosis. Best Practice and Research in Clinical Rheumatology, 2021, 35, 101667.	3.3	9
39	Botulinum toxin in the management of primary and secondary Raynaud's phenomenon. Best Practice and Research in Clinical Rheumatology, 2021, 35, 101684.	3.3	12
40	Understanding COVID‑19 Risk in Patients with Immune Mediated Inflammatory Diseases: A Population‑based analysis of SARS‑CoV‑2 Testing. Arthritis Care and Research, 2021, , .	3.4	8
41	Innovations in systemic sclerosis. Best Practice and Research in Clinical Rheumatology, 2021, 35, 101708.	3.3	0
42	Diagnosis and Classification of Systemic Lupus Erythematosus. , 2021, , 51-66.		1
43	Effectiveness of initial methotrexate-based treatment approaches in early rheumatoid arthritis: an elicitation of rheumatologists' beliefs. Rheumatology, 2021, 60, 3570-3578.	1.9	2
44	New lupus criteria: a critical view. Current Opinion in Rheumatology, 2021, 33, 205-210.	4.3	8
45	Hydroxychloroquine shortages during the COVID-19 pandemic. Annals of the Rheumatic Diseases, 2021, 80, e31-e31.	0.9	26
46	Response to: 'Role of ANA testing in the classification of patients with systemic lupus erythematosus' by Pisetsky <i>et al</i>. Annals of the Rheumatic Diseases, 2021, 80, e125-e125.	0.9	1
47	The Scleroderma Patient-centered Intervention Network Self-Management (SPIN-SELF) Program: protocol for a two-arm parallel partially nested randomized controlled feasibility trial with progression to full-scale trial. Trials, 2021, 22, 856.	1.6	4
48	Associations Between Classification Criteria Items in Systemic Lupus Erythematosus. Arthritis Care and Research, 2020, 72, 1820-1826.	3.4	28
49	Classification of IgG4‑Related Disease: A Medical Marvel of Our Time. Arthritis and Rheumatology, 2020, 72, 1-3.	5.6	1
50	Reply. Arthritis and Rheumatology, 2020, 72, 695-696.	5.6	1
51	Safety and efficacy of abatacept in early diffuse cutaneous systemic sclerosis (ASSET): open-label extension of a phase 2, double-blind randomised trial. Lancet Rheumatology, The, 2020, 2, e743-e753.	3.9	34
52	American College of Rheumatology Guidance for the Management of Rheumatic Disease in Adult Patients During the COVID‑19 Pandemic: Version 2. Arthritis and Rheumatology, 2020, 72, e1-e12.	5.6	64
53	Performance of the 2019 EULAR/ACR classification criteria for systemic lupus erythematosus in early disease, across sexes and ethnicities. Annals of the Rheumatic Diseases, 2020, 79, 1333-1339.	0.9	35
54	Classifying and diagnosing systemic lupus erythematosus in the 21st century. Rheumatology, 2020, 59, v4-v11.	1.9	52

#	Article	IF	Citations
55	Current Therapeutic Approaches in Scleroderma: Clinical Models of Effective Antifibrotic Therapies. Current Treatment Options in Rheumatology, 2020, 6, 382-393.	1.4	1
56	New Criteria for Lupus. Current Rheumatology Reports, 2020, 22, 18.	4.7	37
57	Predictors of progression in systemic sclerosis patients with interstitial lung disease. European Respiratory Journal, 2020, 55, 1902026.	6.7	134
58	Reply. Arthritis and Rheumatology, 2020, 72, 860-861.	5.6	0
59	American College of Rheumatology Guidance for the Management of Rheumatic Disease in Adult Patients During the COVIDâ€19 Pandemic: Version 1. Arthritis and Rheumatology, 2020, 72, 1241-1251.	5.6	142
60	Reply. Arthritis and Rheumatology, 2020, 72, 1404-1404.	5.6	0
61	Riociguat in patients with early diffuse cutaneous systemic sclerosis (RISE-SSc): randomised, double-blind, placebo-controlled multicentre trial. Annals of the Rheumatic Diseases, 2020, 79, 618-625.	0.9	71
62	Response to: â€˜Correspondence on â€˜Performance of the 2019 EULAR/ACR classification criteria for systemic lupus erythematosus in early disease, across sexes and ethnicitiesâ€™â€™ by Ronnelid et al. Annals of the Rheumatic Diseases, 2020, , annrheumdis-2020-219314.	0.9	2
63	The Scleroderma Patient-Centered Intervention Network Self-Management Program: Protocol for a Randomized Feasibility Trial. JMIR Research Protocols, 2020, 9, e16799.	1.0	7
64	Systemic sclerosis: To subset or not to subset, that is the question. European Journal of Rheumatology, 2020, 7, 222-227.	0.6	13
65	How Do Patients With Newly Diagnosed Systemic Lupus Erythematosus Present? A Multicenter Cohort of Early Systemic Lupus Erythematosus to Inform the Development of New Classification Criteria. Arthritis and Rheumatology, 2019, 71, 91-98.	5.6	93
66	An interim report of the Scleroderma Clinical Trials Consortium working groups. Journal of Scleroderma and Related Disorders, 2019, 4, 17-27.	1.7	13
67	2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. Annals of the Rheumatic Diseases, 2019, 78, 1151-1159.	0.9	759
68	2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus. Arthritis and Rheumatology, 2019, 71, 1400-1412.	5.6	1,098
69	Fatigue severity in anti-nuclear antibody-positive individuals does not correlate with pro-inflammatory cytokine levels or predict imminent progression to symptomatic disease. Arthritis Research and Therapy, 2019, 21, 223.	3.5	13
70	Difference between SLE classification and diagnosis and importance of attribution. Response to: â€˜Do the 2019 EULAR/ACR SLE classification criteria close the door on certain groups of SLE patients?â€™ by Chi et al. Annals of the Rheumatic Diseases, 2019, , annrheumdis-2019-216338.	0.9	4
71	Multicriteria decision analysis process to develop new classification criteria for systemic lupus erythematosus. Annals of the Rheumatic Diseases, 2019, 78, 634-640.	0.9	51
72	Guidelines and Recommendations Towards Evidence-Based Management of Systemic Sclerosis. Current Treatment Options in Rheumatology, 2019, 5, 115-126.	1.4	1

#	ARTICLE	IF	CITATIONS
73	Ethnic Variations in Systemic Sclerosis Disease Manifestations, Internal Organ Involvement, and Mortality. Journal of Rheumatology, 2019, 46, 1103-1108.	2.0	46
74	Response to: 'Development and initial validation of diagnostic gene signatures for systemic lupus erythematosus' by Wang et al. Annals of the Rheumatic Diseases, 2019, 80, annrheumdis-2019-216807.	0.9	0
75	Response to: 'New 2019 SLE EULAR/ACR classification criteria are valuable for distinguishing patients with SLE from patients with pSS' by Assan et al. Annals of the Rheumatic Diseases, 2019, , annrheumdis-2019-216250.	0.9	1
76	Use of Consensus Methodology to Determine Candidate Items for Systemic Lupus Erythematosus Classification Criteria. Journal of Rheumatology, 2019, 46, 721-726.	2.0	45
77	Generation of a Core Set of Items to Develop Classification Criteria for Scleroderma Renal Crisis Using Consensus Methodology. Arthritis and Rheumatology, 2019, 71, 964-971.	5.6	41
78	Reply. Arthritis Care and Research, 2019, 71, 696-697.	3.4	2
79	Advanced Epidemiologic Methods for the Study of Rheumatic and Musculoskeletal Diseases. Rheumatic Disease Clinics of North America, 2018, 44, xv-xvi.	1.9	2
80	Venous Thromboembolism in Systemic Sclerosis: Prevalence, Risk Factors, and Effect on Survival. Journal of Rheumatology, 2018, 45, 942-946.	2.0	8
81	Propensity Score Methods for Bias Reduction in Observational Studies of Treatment Effect. Rheumatic Disease Clinics of North America, 2018, 44, 203-213.	1.9	56
82	Applied Bayesian Methods in the Rheumatic Diseases. Rheumatic Disease Clinics of North America, 2018, 44, 361-370.	1.9	4
83	Use of "Provisional" Designation for Response Criteria. Arthritis Care and Research, 2018, 70, 811-812.	3.4	3
84	Multicenter Delphi Exercise to Identify Important Key Items for Classifying Systemic Lupus Erythematosus. Arthritis Care and Research, 2018, 70, 1488-1494.	3.4	48
85	Exercise habits and factors associated with exercise in systemic sclerosis: a Scleroderma Patient-centered Intervention Network (SPIN) cohort study. Disability and Rehabilitation, 2018, 40, 1997-2003.	1.8	17
86	Performance of Antinuclear Antibodies for Classifying Systemic Lupus Erythematosus: A Systematic Literature Review and Meta‐Regression of Diagnostic Data. Arthritis Care and Research, 2018, 70, 428-438.	3.4	129
87	Developing and Refining New Candidate Criteria for Systemic Lupus Erythematosus Classification: An International Collaboration. Arthritis Care and Research, 2018, 70, 571-581.	3.4	91
88	AI-09…T follicular helper (Tfh) cells are increased in asymptomatic anti-nuclear antibody (ANA)+ individuals and appear to play a role in epitope spreading. , 2018, , .		0
89	The presence of anti-nuclear antibodies alone is associated with changes in B cell activation and T follicular helper cells similar to those in systemic autoimmune rheumatic disease. Arthritis Research and Therapy, 2018, 20, 264.	3.5	26
90	Patient-reported outcome instruments for assessing Raynaud's phenomenon in systemic sclerosis: A SCTC vascular working group report. Journal of Scleroderma and Related Disorders, 2018, 3, 249-252.	1.7	33

#	Article	IF	Citations
91	Epidemiology and Survival of Systemic Sclerosis-Systemic Lupus Erythematosus Overlap Syndrome. Journal of Rheumatology, 2018, 45, 1406-1410.	2.0	36
92	The Scleroderma Patient-Centered Intervention Network Cohort: baseline clinical features and comparison with other large scleroderma cohorts. Rheumatology, 2018, 57, 1623-1631.	1.9	53
93	Presence of an interferon signature in individuals who are anti-nuclear antibody positive lacking a systemic autoimmune rheumatic disease diagnosis. Arthritis Research and Therapy, 2017, 19, 41.	3.5	34
94	Progress in the clinical classification of systemic sclerosis. Current Opinion in Rheumatology, 2017, 29, 568-573.	4.3	9
95	Development, Sensibility, and Validity of a Systemic Autoimmune Rheumatic Disease Case Ascertainment Tool. Journal of Rheumatology, 2017, 44, 18-23.	2.0	6
96	Exhaled Nitric Oxide in Systemic Sclerosis Lung Disease. Canadian Respiratory Journal, 2017, 2017, 1-8.	1.6	11
97	Defining Skin Ulcers in Systemic Sclerosis: Systematic Literature Review and Proposed World Scleroderma Foundation (WSF) Definition. Journal of Scleroderma and Related Disorders, 2017, 2, 115-120.	1.7	62
98	Controversies: molecular vs. clinical systemic sclerosis classification. Journal of Scleroderma and Related Disorders, 2016, 1, 277-285.	1.7	16
99	Systemic sclerosis trial design moving forward. Journal of Scleroderma and Related Disorders, 2016, 1, 177-180.	1.7	42
100	Qualitative Methods in Systemic Sclerosis Research. Journal of Rheumatology, 2016, 43, 1265-1267.	2.0	13
101	Online obituaries are a reliable and valid source of mortality data. Journal of Clinical Epidemiology, 2016, 79, 167-168.	5.0	17
102	Reply. Arthritis Care and Research, 2016, 68, 1049-1050.	3.4	1
103	The American College of Rheumatology Provisional Composite Response Index for Clinical Trials in Early Diffuse Cutaneous Systemic Sclerosis. Arthritis Care and Research, 2016, 68, 167-178.	3.4	13
104	Prevalence and risk factors of low bone mineral density in psoriatic arthritis: A systematic review. Seminars in Arthritis and Rheumatism, 2016, 46, 174-182.	3.4	39
105	Sex disparities in systemic sclerosis-associated pulmonary arterial hypertension: a cohort study. Arthritis Research and Therapy, 2016, 18, 30.	3.5	28
106	The American College of Rheumatology Provisional Composite Response Index for Clinical Trials in Early Diffuse Cutaneous Systemic Sclerosis. Arthritis and Rheumatology, 2016, 68, 299-311.	5.6	110
107	New Classification Criteria for Systemic Sclerosis (Scleroderma). Rheumatic Disease Clinics of North America, 2015, 41, 383-398.	1.9	32
108	Specificity of Systemic Sclerosis Classification Criteria. Journal of Rheumatology, 2015, 42, 2512-2512.	2.0	3

#	ARTICLE	IF	CITATIONS
109	Psoriatic Arthritis Mutilans: Clinical and Radiographic Criteria. A Systematic Review. Journal of Rheumatology, 2015, 42, 1432-1438.	2.0	22
110	Safety and Effectiveness of Mycophenolate in Systemic Sclerosis. A Systematic Review. PLoS ONE, 2015, 10, e0124205.	2.5	66
111	Distinctions Between Diagnostic and Classification Criteria?. Arthritis Care and Research, 2015, 67, 891-897.	3.4	386
112	New ACR EULAR Guidelines for Systemic Sclerosis Classification. Current Rheumatology Reports, 2015, 17, 32.	4.7	46
113	Survival in rheumatoid arthritisâ€associated pulmonary arterial hypertension compared with idiopathic pulmonary arterial hypertension. Respirology, 2015, 20, 481-487.	2.3	16
114	Lung Function and Survival in Systemic Sclerosis Interstitial Lung Disease. Journal of Rheumatology, 2014, 41, 2326-2328.	2.0	10
115	The Effect of Male Sex on Survival in Systemic Sclerosis. Journal of Rheumatology, 2014, 41, 2193-2200.	2.0	56
116	Peter Lee, MD, FRCPC, FRACP, 1943â€"2014. Journal of Rheumatology, 2014, 41, 2490-2490.	2.0	0
117	Multicriteria decision analysis methods with 1000Minds for developing systemic sclerosis classification criteria. Journal of Clinical Epidemiology, 2014, 67, 706-714.	5.0	52
118	2013 Classification Criteria for Systemic Sclerosis: An American College of Rheumatology/European League Against Rheumatism Collaborative Initiative. Arthritis and Rheumatism, 2013, 65, 2737-2747.	6.7	2,359
119	2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative. Annals of the Rheumatic Diseases, 2013, 72, 1747-1755.	0.9	1,705
120	Inflammatory Arthritis, Sacroiliitis, and Morphea: Evidence of a Systemic Inflammatory Disease. Case Reports in Rheumatology, 2013, 2013, 1-3.	0.6	3
121	Warfarin in Systemic Sclerosis-associated and Idiopathic Pulmonary Arterial Hypertension. A Bayesian Approach to Evaluating Treatment for Uncommon Disease. Journal of Rheumatology, 2012, 39, 276-285.	2.0	75
122	Dual therapy in IPAH and SSc-PAH. A qualitative systematic review. Respiratory Medicine, 2012, 106, 730-739.	2.9	26
123	Items for developing revised classification criteria in systemic sclerosis: Results of a consensus exercise. Arthritis Care and Research, 2012, 64, 351-357.	3.4	49
124	Validation of potential classification criteria for systemic sclerosis. Arthritis Care and Research, 2012, 64, 358-367.	3.4	77
125	Biologic Therapy for Systemic Sclerosis: A Systematic Review. Journal of Rheumatology, 2011, 38, 289-296.	2.0	52
126	Effect of Warfarin on Survival in Scleroderma-associated Pulmonary Arterial Hypertension (SSc-PAH) and Idiopathic PAH. Belief Elicitation for Bayesian Priors. Journal of Rheumatology, 2011, 38, 462-469.	2.0	30

#	Article	IF	Citations
127	Bayesian Inference: Statistical Gimmick or Added Value?. Journal of Rheumatology, 2011, 38, 794-796.	2.0	4
128	Methods to elicit beliefs for Bayesian priors: a systematic review. Journal of Clinical Epidemiology, 2010, 63, 355-369.	5.0	140
129	A valid and reliable belief elicitation method for Bayesian priors. Journal of Clinical Epidemiology, 2010, 63, 370-383.	5.0	66
130	Magnetic Resonance Imaging of the Hand in Systemic Sclerosis. Journal of Rheumatology, 2009, 36, 961-964.	2.0	57
131	Ethnic Influence on Disease Manifestations and Autoantibodies in Chinese-Descent Patients with Systemic Sclerosis. Journal of Rheumatology, 2009, 36, 787-793.	2.0	31
132	Shifting Our Thinking About Uncommon Disease Trials: The Case of Methotrexate in Scleroderma. Journal of Rheumatology, 2009, 36, 323-329.	2.0	71
133	Classification criteria in rheumatic diseases: A review of methodologic properties. Arthritis and Rheumatism, 2007, 57, 1119-1133.	6.7	122
134	Is self-reported improvement in osteoarthritis pain and disability reflected in objective measures?. Journal of Rheumatology, 2007, 34, 159-64.	2.0	22
135	Classification criteria for systemic sclerosis subsets. Journal of Rheumatology, 2007, 34, 1855-63.	2.0	34
136	EVOLUTION AND OUTCOMES OF A RAPID RESPONSE TEAM. Chest, 2006, 130, 218S.	0.8	68
137	Intrathoracic arteritis: a paraneoplastic presentation of malignant melanoma. Journal of Rheumatology, 2006, 33, 820-1.	2.0	0
138	Quality of life and functional status in systemic sclerosis compared to other rheumatic diseases. Journal of Rheumatology, 2006, 33, 1117-22.	2.0	60
139	Scleroderma: health services utilization from patients' perspective. Journal of Rheumatology, 2006, 33, 1123-7.	2.0	19
140	Ethnic variation in disease patterns and health outcomes in systemic lupus erythematosus. Journal of Rheumatology, 2006, 33, 1990-5.	2.0	46
141	Pulmonary veno-occlusive disease and scleroderma associated pulmonary hypertension. Journal of Rheumatology, 2006, 33, 2347-50.	2.0	45
142	The health assessment questionnaire disability index and scleroderma health assessment questionnaire in scleroderma trials: An evaluation of their measurement properties. Arthritis and Rheumatism, 2005, 53, 256-262.	6.7	67
143	Developing a pulmonary hypertension health passport to improve care: A qualitative study. Canadian Journal of Respiratory, Critical Care, and Sleep Medicine, 0, , 1-6.	0.5	0